Record Details

Spectral, anticancer and molecular docking studies of paddle-wheel complex tetrakis(μ-acetato) bis(2-pyridone)dicopper(II) against MCF-7 cell line

NOPR - NISCAIR Online Periodicals Repository

View Archive Info
 
 
Field Value
 
Title Spectral, anticancer and molecular docking studies of paddle-wheel complex tetrakis(μ-acetato) bis(2-pyridone)dicopper(II) against MCF-7 cell line
 
Creator Vennila, S
Deepa, K
Shalini, A
Nagaraja, K S
Karnan, C
Lakshmi, L
Muthuvel, I
Thirunarayanan, G
 
Subject Tetrakis(μ-acetato)bis(2-pyridone)dicopper(II) (Cu2TAP)
Spectral studies
Anticancer activity
Molecular docking
 
Description 1044-1052
Tetrakis(μ-acetato)bis(2-pyridone)dicopper(II) (Cu2TAP) has been obtained unexpectedly during refluxing of HPMP, 2-
methyl pyridine and CuCl2 in ethanol in 1:1:1mole ratio. The metal complex has been characterized by FT-IR, Raman, UVVis
and EPR spectroscopy. The complex shows characteristic NH and CO stretching in IR and Raman. UV-Vis shows bands
at 293 and 242 nm due to π→π* and n→π* transitions. The compound emits strong fluorescence bands at 726 and 765 nm
when excited at 360 and 380 nm respectively. EPR indicates a strong anti-ferro magnetic interaction between the two Cu (II)
centers as bridged by the acetate ligands. The cytotoxicity activity has been performed by the MTT assay against MCF-7
breast cancer cells. The binding modes of Cu2TAPin the active pocket of the target protein Human estrogen receptor alpha
(PDB ID: HERT) has been found to be the H-bonding and weak metal-protein interaction. The complex-HERT interaction
energy is –8.40 kcal/mol compared to its interaction with doxorubicin (–7.90kcal/mol). Thus Cu2TAP can be considered as
an anticancer agent and may have OLED applications.
 
Date 2024-10-23T09:47:42Z
2024-10-23T09:47:42Z
2024-10
 
Type Article
 
Identifier 2583-1321 (Online); 0019-5103 (Print)
http://nopr.niscpr.res.in/handle/123456789/64732
https://doi.org/10.56042/ijc.v63i10.12807
 
Language en
 
Publisher NIScPR-CSIR, India
 
Source IJC Vol.63(10) [October 2024]